Blocking human epidermal growth factor receptor 2 (HER 3) signaling using antibodies (such as trastuzumab, pertuzumab, and trastuzumab-emtasine) has improved outcomes for patients with HER2-positive breast cancer when combined with chemotherapy. Here, ERBB2 is linked to breast carcinoma.